Premium
In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET
Author(s) -
Mecca Adam P.,
Chen MingKai,
O'Dell Ryan S.,
Naganawa Mika,
Toyonaga Takuya,
Godek Tyler A.,
Harris Joanna E.,
Bartlett Hugh H.,
Zhao Wenzhen,
Nabulsi Nabeel B.,
Wyk Brent C. Vander,
Varma Pradeep,
Arnsten Amy F. T.,
Huang Yiyun,
Carson Richard E.,
Dyck Christopher H.
Publication year - 2020
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1002/alz.12097
Subject(s) - positron emission tomography , neuroscience , biomarker , alzheimer's disease , pet imaging , medicine , cognitive impairment , synaptic vesicle , pathology , disease , nuclear medicine , biology , biochemistry , vesicle , membrane
Synaptic loss is a robust and consistent pathology in Alzheimer's disease (AD) and the major structural correlate of cognitive impairment. Positron emission tomography (PET) imaging of synaptic vesicle glycoprotein 2A (SV2A) has emerged as a promising biomarker of synaptic density. Methods We measured SV2A binding in 34 participants with early AD and 19 cognitively normal (CN) participants using [ 11 C]UCB‐J PET and a cerebellar reference region for calculation of the distribution volume ratio. Results We observed widespread reductions of SV2A binding in medial temporal and neocortical brain regions in early AD compared to CN participants. These reductions were largely maintained after correction for volume loss and were more extensive than decreases in gray matter volume. Conclusion We were able to measure widespread synaptic loss due to AD using [ 11 C]UCB‐J PET. Future studies will continue to evaluate the utility of SV2A PET for tracking AD progression and for monitoring potential therapies.